Kexing Biopharm’s innovative drug “GB19 Injection” received approval from NMPA to conduct clinical trials in China

Recently, Kexing Biopharm's innovative drug "GB19 Injection" for the treatment of systemic lupus erythematosus (SLE) received approval from National Medical Products Administration (NMPA) to conduct clinical trials in China.

 

Differentiated Innovative Targeting Mechanism

 

GB19 Injection targets BDCA2, a receptor specifically expressed on the surface of plasmacytoid dendritic cells (pDCs). Its mechanism of action is distinct from that of currently approved therapies that primarily targeting the B-cell pathway. By specifically binding to BDCA2, GB19 inhibits the production of type I interferon by pDC cells, thereby modulating the pathogenic feedback loop between innate and adaptive immunity. In preclinical studies, GB19 demonstrated high potency, favorable bioavailability, sustained target inhibition for over 90 days, low immunogenicity, and an excellent safety profile. If successfully developed, it is expected to provide new treatment options for patients with autoimmune diseases associated with interferon pathway dysregulation including SLE.

 

SLE Enters a New Stage of Treatment


Systemic lupus erythematosus (SLE) is a systemic autoimmune disease related to multiple factors, including genetic susceptibility, sex hormones, and environmental trigger such as infection. Its main clinical characteristics include multi-system and multi-organ involvement, recurrent relapses, and the immune –mediated damage to self-tissues. SLE can lead to various complications, including lupus nephritis and neuropsychiatric manifestations, posing serious threats to patients' survival and quality of life. The global patient population is large, with a higher incidence in women of childbearing age compared with in men.


With increased global awareness of SLE and advancements in the development of novel biologics, future SLE treatment will become more precise and personalized. Treatment goals will evolve from simply controlling disease activity to achieving comprehensive remission with low activity, clinical remission, and minimal long-term damage.


The approval of GB19 for clinical trials is a significant achievement for the company's continuous innovation in the treatment of autoimmune diseases and an important step in its global strategy for innovative drugs. Kexing Biopharm adheres to an "innovation + internationalization" strategy, deeply exploring unmet clinical needs in oncology and autoimmune diseases, and is committed to becoming an innovative international biopharmaceutical company.

https://www.kexingbiopharm.com/
Kexing Biopharm

  • Related Posts

    Chinesia Helps Global Learners Build Practical Chinese Skills Through One Connected Learning Platform
    • adminadmin
    • November 20, 2026

    Chinese learning designed for real communication Many learners can recognize Chinese words and grammar but still feel uncertain when they need to speak in real situations. Chinesia is designed to…

    Continue reading
    CRET Technology Explained: How Wash-Free Homogeneous CLIA Works
    • adminadmin
    • November 20, 2026

    Industry Background and the Diagnostic Challenge In vitro diagnostic (IVD) testing has long relied on chemiluminescence immunoassay (CLIA) systems that depend on magnetic bead separation, multiple washing steps, and complex…

    Continue reading

    Leave a Reply

    Mechanical Equipment & Tool Parts

    CNC Machining Services for Performance Hardware Brands, 2026

    • November 20, 2026

    Shenzhen Servo Motor Driver Manufacturer CNC Machining 2026

    • November 20, 2026

    CNC Machining Service Pricing and NDA Protection Explained

    • November 20, 2026

    Sports Lighting Energy Management: How to Reduce Operating Costs Without Compromising Lighting Quality

    • November 20, 2026

    Which HVDC Suppliers Balance Efficiency And Lifecycle Cost

    • November 20, 2026

    Aokai 10 mg Filter Bags: Baghouse Emission Control Quotes

    • November 20, 2026